Search Results 251-260 of 23790 for prostate cancer

1. A Study of MRI-Targeted Biopsy Compared to Standard Ultrasound Guided Biopsy for the Diagnosis of Prostate Cancer - Mayo Clinic

   ... prostate biopsies compared to standard 12-core trans-rectal ultrasound guided (TRUS) prostate biopsies for prostate cancer. Participation eligibility.

2. Donald J. Tindall, Ph.D. - Mayo Clinic Faculty Profiles

   ... cancer cells survive after androgen ablation, the most common therapy for advanced prostate cancer. Prostate cancer is initially an androgen-dependent tumor.

3. Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease - Mayo Clinic

   Also, we will evaluate whether the peripheral blood immune cell function is different in B/AA prostate cancer patients with metastatic disease as compared with ...

4. Focal Prostate Ablation Utilizing TULSA Profound System - Mayo Clinic

   The primary hypotheses are that the TULSA-Procedure is safe and effective treatment of intermediate grade prostate cancer over 2 years. The primary endpoint ...

5. Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer - Mayo Clinic

   National Comprehensive Cancer Network (NCCN) (Prostate Cancer version 4.2022) low- to intermediate-risk prostate adenocarcinoma; Eastern Cooperative Oncology ...

6. In case you missed it: This week's Top 5 stories on social media - Mayo Clinic News Network

   Mayo Clinic is leading the way with a new treatment for advanced prostate cancer, specifically for prostate-specific membrane antigen-positive metastatic ...

7. Clinical trials - Oncology (Medical)

   Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and ...

8. Cabazitaxel (intravenous route) - Mayo Clinic

   ... (cancer that has already spread) castration-resistant prostate cancer (prostate cancer that cannot be treated by surgery or medicines that lower testosterone).

9. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer - Mayo Clinic

   177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer. Print details. Share ...

10. Publications - Alton O. Sartor, M.D. - Mayo Clinic

    Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 2024 Oct 17 [Epub ...